Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06787053Recruiting
MRI imaging for oxygen-starved tumors
This study uses MRI scans to find areas of low oxygen in tumors and see if adjusting radiation treatment can help. It is open to adults with bladder, cervix, or prostate cancer who are getting radiation therapy at the Christie NHS Foundation Trust.
ManchesterAges 18 years+ - NCT06787313Recruiting
Precision palliative care for advanced esophageal cancer
This trial studies a personalized approach to palliative care for people with advanced or recurrent esophageal cancer who are being treated with immunotherapy. It aims to improve quality of life and symptom management.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06787625Recruiting
Growing tumor models from colorectal cancer and liver metastases
This study takes samples from colorectal cancer that has spread to the liver and grows them in the lab. The goal is to create models that can help researchers understand the cancer better and find new treatments.
RomeAges 18 years+ - NCT06787911RecruitingPhase 2
Donafenib and immunotherapy before surgery for advanced thyroid cancer
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
ShanghaiAges 18–80 - NCT06788366Recruiting
AI tool to predict outcomes in metastatic lung cancer
This trial is testing whether artificial intelligence can help predict how well people with advanced non-small cell lung cancer (NSCLC) respond to immunotherapy or chemo-immunotherapy. If you have stage IV NSCLC and have started this treatment, your data may help build a better prediction tool.
MilanAges 18 years+ - NCT06788548Recruiting
Fluorescence-Guided Surgery for Early Stomach Cancer
This trial tests a new technique that uses a special dye to highlight the first lymph nodes where stomach cancer might spread, allowing surgeons to remove only the necessary nodes during surgery. The goal is to reduce side effects while still effectively treating the cancer.
Beijing, Beijing MunicipalityAges 18–80 - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT06791005RecruitingPhase 3
Timing of carbon nanoparticles injection for thyroid cancer
This trial tests whether the timing of a carbon nanoparticle injection during thyroid cancer surgery improves outcomes. It may help patients who need their whole thyroid removed and have cancer in both lobes or spread to lymph nodes.
Xi'an, ShaanxiAges 16–80 - NCT06791083RecruitingPhase 2
Envafolimab, Fruquintinib, and chemo before gastric cancer surgery
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT06791148RecruitingPhase 2
Low-dose radiation plus chemo and immunotherapy for advanced stomach cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06791941Recruiting
Studying therapy resistance in recurrent head and neck cancer
This study looks at why some head and neck cancers come back after treatment. It will test tumor tissue from people having surgery to see if certain proteins (mutant p53 and YAP) are linked to treatment resistance. Your participation could help researchers understand how to better treat these cancers in the future.
Roma, RomeAges 18 years+ - NCT06792162RecruitingPhase 2
Immunotherapy and targeted therapy trial for advanced gastric cancer
This trial tests a combination of two drugs: carilizumab (an immunotherapy) and apatinib (a targeted therapy) for patients with unresectable stage III or IV gastric cancer that has a specific DNA repair problem (dMMR). The goal is to see if this treatment can help shrink tumors and improve outcomes.
BeijingAges 18 years+ - NCT06792604Recruiting
Methylation test for anal cancer screening
This study is testing a new way to screen for anal cancer by looking at DNA methylation in cells collected from the anus. It may help people at higher risk for anal cancer find out earlier if they need further tests.
Paris, Île-de-France RegionAges 18 years+ - NCT06792786Recruiting
Study of Chemo-Immunotherapy and Radiation for Esophageal Cancer with Blood Monitoring
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
Jinhua, ZhejiangAges 18–75 - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT06793709Recruiting
Study of Tasfygo for bile duct cancer with FGFR2 gene change
This study is watching people with a certain type of bile duct cancer that has a specific gene change (FGFR2 fusion). It looks at what happens when they take the drug Tasfygo after their cancer did not respond to chemotherapy.
TokyoAges Any age - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06796764Recruiting
Breathing tube safety during endoscopy in people with obesity
This trial tests a special breathing tube to see if it can prevent low oxygen levels during sedated endoscopy in people with obesity. If you are scheduled for both an upper endoscopy and colonoscopy, this study may help make the procedure safer.
Hangzhou, ZhejiangAges 18–70 - NCT06795087Recruiting
Medication Use After Genitourinary Cancer Surgery
This study looks at the medications patients take after surgery for bladder, kidney, or prostate cancer. The goal is to understand how these medications are used and help improve recovery.
Charlotte, North CarolinaAges 18 years+ - NCT06795529Recruiting
Palliative care support for metastatic breast cancer
This study tests a palliative care program designed to improve quality of life for people with metastatic breast cancer. It may help you better manage symptoms and coordinate care with your oncology team.
Boston, MassachusettsAges 18 years+ - NCT06797531Recruiting
Ribociclib Real-World Study in Early Breast Cancer
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
RiyadhAges 18–99 - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06799481Recruiting
Home-based exercise to help brain tumor survivors with thinking and memory
This study tests whether a virtual home-based exercise program can improve thinking and memory problems caused by brain tumor treatment in teens and young adults. It also looks at how exercise affects gut health.
Atlanta, GeorgiaAges 15–39
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,144 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.